NCT04847895

Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications

Observation of Treatment Patterns With Lucentis® (Ranibizumab) in Real-life Conditions in All Approved Indications

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 5,500 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is designed as an observational, non-interventional, multicenter, open label, single arm study in patients being treated with Lucentis® for any approved indication included in the local product posology.

Detailed description

The prospective observation period per patient will be up to 24 months. A minimum of one follow-up visit per year is required in order to maintain patient's participation in the study. The baseline visit will be used to assess eligibility and collect baseline characteristics information. The follow-up visits will take place at a frequency defined as per investigator's discretion. The study eye is defined as the first eye treated during the study, the other eye will be considered as the fellow eye. If both eyes are treated at baseline, the right eye will be chosen as the study eye.

Conditions

• Neovascular (Wet) Age-related Macular Degeneration

Interventions

Type	Name	Description
DRUG	Lucentis	There is no treatment allocation. Patients administered Lucentis by prescription that have started before inclusion of the patient into the study will be enrolled.

Timeline

• Start date: 2015-06-01
• Primary completion: 2021-03-31
• Completion: 2021-03-31
• First posted: 2021-04-19
• Last updated: 2021-04-19

Locations

175 sites across 3 countries: Germany, Netherlands, Switzerland